t stat 1 Search Results


phospho stat1  (Bethyl)
93
Bethyl phospho stat1
FIG. 1. Pharmacological analyses of IFN-induced phosphorylation of IFNAR1 degron. (A) Binding of 35S-Trcp2 to GST-IFNAR1 (wild type [WT] or S535 539A mutant [SA]) upon their phosphorylation using CK1-depleted lysates from 293T cells treated with IFN- as indicated. Levels of GST-IFNAR1 are analyzed by Coomassie blue staining. The SA mutant migrates more slowly in SDS-PAGE due to the presence of four additional amino acids in the linker (31). (B) The effects of various pharmacologic kinase inhibitors (whose activities were verified in kinase-specific assays; data not shown) on phosphorylation of GST-IFNAR1 by the CK1-depleted lysate from IFN--treated (for 10 min) cells were analyzed by subsequent binding of 35S-labeled Trcp2, as described for panel A. (C) Immunoblot analysis of Flag-IFNAR1 immunopurified from U3A human cells pretreated with kinase inhibitors and then treated with IFN- as indicated. (D and E) Endogenous IFNAR1 immunoprecipitated from the lysates from 293T cells (treated as indicated) was analyzed as in panel C. (F) Immunoblot analysis of IFNAR1 and <t>STAT1</t> in mouse embryo fibroblasts not treated (Mock) or treated with IFN- (500 IU/ml) with or without pretreatment with JAK inhibitor I (JI) or PKD inhibitor CID755673 (CID) as indicated.
Phospho Stat1, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+stat+1/STAT1+Antibody/10__1128_slash_mcb__01154___10-62-29-39
Average 93 stars, based on 1 article reviews
phospho stat1 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
mouse monoclonal antibody mab  (Fortis Life Sciences)
90
Fortis Life Sciences mouse monoclonal antibody mab
FIG. 1. Pharmacological analyses of IFN-induced phosphorylation of IFNAR1 degron. (A) Binding of 35S-Trcp2 to GST-IFNAR1 (wild type [WT] or S535 539A mutant [SA]) upon their phosphorylation using CK1-depleted lysates from 293T cells treated with IFN- as indicated. Levels of GST-IFNAR1 are analyzed by Coomassie blue staining. The SA mutant migrates more slowly in SDS-PAGE due to the presence of four additional amino acids in the linker (31). (B) The effects of various pharmacologic kinase inhibitors (whose activities were verified in kinase-specific assays; data not shown) on phosphorylation of GST-IFNAR1 by the CK1-depleted lysate from IFN--treated (for 10 min) cells were analyzed by subsequent binding of 35S-labeled Trcp2, as described for panel A. (C) Immunoblot analysis of Flag-IFNAR1 immunopurified from U3A human cells pretreated with kinase inhibitors and then treated with IFN- as indicated. (D and E) Endogenous IFNAR1 immunoprecipitated from the lysates from 293T cells (treated as indicated) was analyzed as in panel C. (F) Immunoblot analysis of IFNAR1 and <t>STAT1</t> in mouse embryo fibroblasts not treated (Mock) or treated with IFN- (500 IU/ml) with or without pretreatment with JAK inhibitor I (JI) or PKD inhibitor CID755673 (CID) as indicated.
Mouse Monoclonal Antibody Mab, supplied by Fortis Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+stat+1/STAT1+Recombinant+Monoclonal+Antibody/pm26479788-455-63-61
Average 90 stars, based on 1 article reviews
mouse monoclonal antibody mab - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
human phospho-stat1 (y701) antibody  (Bio-Techne corporation)
90
Bio-Techne corporation human phospho-stat1 (y701) antibody
FIG. 1. Pharmacological analyses of IFN-induced phosphorylation of IFNAR1 degron. (A) Binding of 35S-Trcp2 to GST-IFNAR1 (wild type [WT] or S535 539A mutant [SA]) upon their phosphorylation using CK1-depleted lysates from 293T cells treated with IFN- as indicated. Levels of GST-IFNAR1 are analyzed by Coomassie blue staining. The SA mutant migrates more slowly in SDS-PAGE due to the presence of four additional amino acids in the linker (31). (B) The effects of various pharmacologic kinase inhibitors (whose activities were verified in kinase-specific assays; data not shown) on phosphorylation of GST-IFNAR1 by the CK1-depleted lysate from IFN--treated (for 10 min) cells were analyzed by subsequent binding of 35S-labeled Trcp2, as described for panel A. (C) Immunoblot analysis of Flag-IFNAR1 immunopurified from U3A human cells pretreated with kinase inhibitors and then treated with IFN- as indicated. (D and E) Endogenous IFNAR1 immunoprecipitated from the lysates from 293T cells (treated as indicated) was analyzed as in panel C. (F) Immunoblot analysis of IFNAR1 and <t>STAT1</t> in mouse embryo fibroblasts not treated (Mock) or treated with IFN- (500 IU/ml) with or without pretreatment with JAK inhibitor I (JI) or PKD inhibitor CID755673 (CID) as indicated.
Human Phospho Stat1 (Y701) Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+stat+1/Human+Phospho-STAT1+(Y701)+Antibody/bio-techne+corporation___mab2894
Average 90 stars, based on 1 article reviews
human phospho-stat1 (y701) antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
human/mouse phospho-stat1 (y701) antibody  (Bio-Techne corporation)
94
Bio-Techne corporation human/mouse phospho-stat1 (y701) antibody
FIG. 1. Pharmacological analyses of IFN-induced phosphorylation of IFNAR1 degron. (A) Binding of 35S-Trcp2 to GST-IFNAR1 (wild type [WT] or S535 539A mutant [SA]) upon their phosphorylation using CK1-depleted lysates from 293T cells treated with IFN- as indicated. Levels of GST-IFNAR1 are analyzed by Coomassie blue staining. The SA mutant migrates more slowly in SDS-PAGE due to the presence of four additional amino acids in the linker (31). (B) The effects of various pharmacologic kinase inhibitors (whose activities were verified in kinase-specific assays; data not shown) on phosphorylation of GST-IFNAR1 by the CK1-depleted lysate from IFN--treated (for 10 min) cells were analyzed by subsequent binding of 35S-labeled Trcp2, as described for panel A. (C) Immunoblot analysis of Flag-IFNAR1 immunopurified from U3A human cells pretreated with kinase inhibitors and then treated with IFN- as indicated. (D and E) Endogenous IFNAR1 immunoprecipitated from the lysates from 293T cells (treated as indicated) was analyzed as in panel C. (F) Immunoblot analysis of IFNAR1 and <t>STAT1</t> in mouse embryo fibroblasts not treated (Mock) or treated with IFN- (500 IU/ml) with or without pretreatment with JAK inhibitor I (JI) or PKD inhibitor CID755673 (CID) as indicated.
Human/Mouse Phospho Stat1 (Y701) Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+stat+1/Human%2FMouse+Phospho-STAT1+(Y701)+Antibody/bio-techne+corporation___af2894
Average 94 stars, based on 1 article reviews
human/mouse phospho-stat1 (y701) antibody - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
human/mouse stat1 p91 antibody  (Bio-Techne corporation)
94
Bio-Techne corporation human/mouse stat1 p91 antibody
FIG. 1. Pharmacological analyses of IFN-induced phosphorylation of IFNAR1 degron. (A) Binding of 35S-Trcp2 to GST-IFNAR1 (wild type [WT] or S535 539A mutant [SA]) upon their phosphorylation using CK1-depleted lysates from 293T cells treated with IFN- as indicated. Levels of GST-IFNAR1 are analyzed by Coomassie blue staining. The SA mutant migrates more slowly in SDS-PAGE due to the presence of four additional amino acids in the linker (31). (B) The effects of various pharmacologic kinase inhibitors (whose activities were verified in kinase-specific assays; data not shown) on phosphorylation of GST-IFNAR1 by the CK1-depleted lysate from IFN--treated (for 10 min) cells were analyzed by subsequent binding of 35S-labeled Trcp2, as described for panel A. (C) Immunoblot analysis of Flag-IFNAR1 immunopurified from U3A human cells pretreated with kinase inhibitors and then treated with IFN- as indicated. (D and E) Endogenous IFNAR1 immunoprecipitated from the lysates from 293T cells (treated as indicated) was analyzed as in panel C. (F) Immunoblot analysis of IFNAR1 and <t>STAT1</t> in mouse embryo fibroblasts not treated (Mock) or treated with IFN- (500 IU/ml) with or without pretreatment with JAK inhibitor I (JI) or PKD inhibitor CID755673 (CID) as indicated.
Human/Mouse Stat1 P91 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+stat+1/Human%2FMouse+STAT1+p91+Antibody/bio-techne+corporation___paf-st1
Average 94 stars, based on 1 article reviews
human/mouse stat1 p91 antibody - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
human stat1 antibody  (Bio-Techne corporation)
91
Bio-Techne corporation human stat1 antibody
FIG. 1. Pharmacological analyses of IFN-induced phosphorylation of IFNAR1 degron. (A) Binding of 35S-Trcp2 to GST-IFNAR1 (wild type [WT] or S535 539A mutant [SA]) upon their phosphorylation using CK1-depleted lysates from 293T cells treated with IFN- as indicated. Levels of GST-IFNAR1 are analyzed by Coomassie blue staining. The SA mutant migrates more slowly in SDS-PAGE due to the presence of four additional amino acids in the linker (31). (B) The effects of various pharmacologic kinase inhibitors (whose activities were verified in kinase-specific assays; data not shown) on phosphorylation of GST-IFNAR1 by the CK1-depleted lysate from IFN--treated (for 10 min) cells were analyzed by subsequent binding of 35S-labeled Trcp2, as described for panel A. (C) Immunoblot analysis of Flag-IFNAR1 immunopurified from U3A human cells pretreated with kinase inhibitors and then treated with IFN- as indicated. (D and E) Endogenous IFNAR1 immunoprecipitated from the lysates from 293T cells (treated as indicated) was analyzed as in panel C. (F) Immunoblot analysis of IFNAR1 and <t>STAT1</t> in mouse embryo fibroblasts not treated (Mock) or treated with IFN- (500 IU/ml) with or without pretreatment with JAK inhibitor I (JI) or PKD inhibitor CID755673 (CID) as indicated.
Human Stat1 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+stat+1/Human+STAT1+Antibody/bio-techne+corporation___mab1490
Average 91 stars, based on 1 article reviews
human stat1 antibody - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier
stat1 antibody  (Bio-Techne corporation)
90
Bio-Techne corporation stat1 antibody
FIG. 1. Pharmacological analyses of IFN-induced phosphorylation of IFNAR1 degron. (A) Binding of 35S-Trcp2 to GST-IFNAR1 (wild type [WT] or S535 539A mutant [SA]) upon their phosphorylation using CK1-depleted lysates from 293T cells treated with IFN- as indicated. Levels of GST-IFNAR1 are analyzed by Coomassie blue staining. The SA mutant migrates more slowly in SDS-PAGE due to the presence of four additional amino acids in the linker (31). (B) The effects of various pharmacologic kinase inhibitors (whose activities were verified in kinase-specific assays; data not shown) on phosphorylation of GST-IFNAR1 by the CK1-depleted lysate from IFN--treated (for 10 min) cells were analyzed by subsequent binding of 35S-labeled Trcp2, as described for panel A. (C) Immunoblot analysis of Flag-IFNAR1 immunopurified from U3A human cells pretreated with kinase inhibitors and then treated with IFN- as indicated. (D and E) Endogenous IFNAR1 immunoprecipitated from the lysates from 293T cells (treated as indicated) was analyzed as in panel C. (F) Immunoblot analysis of IFNAR1 and <t>STAT1</t> in mouse embryo fibroblasts not treated (Mock) or treated with IFN- (500 IU/ml) with or without pretreatment with JAK inhibitor I (JI) or PKD inhibitor CID755673 (CID) as indicated.
Stat1 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+stat+1/STAT1+Antibody/bio-techne+corporation___nb100-56314
Average 90 stars, based on 1 article reviews
stat1 antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


FIG. 1. Pharmacological analyses of IFN-induced phosphorylation of IFNAR1 degron. (A) Binding of 35S-Trcp2 to GST-IFNAR1 (wild type [WT] or S535 539A mutant [SA]) upon their phosphorylation using CK1-depleted lysates from 293T cells treated with IFN- as indicated. Levels of GST-IFNAR1 are analyzed by Coomassie blue staining. The SA mutant migrates more slowly in SDS-PAGE due to the presence of four additional amino acids in the linker (31). (B) The effects of various pharmacologic kinase inhibitors (whose activities were verified in kinase-specific assays; data not shown) on phosphorylation of GST-IFNAR1 by the CK1-depleted lysate from IFN--treated (for 10 min) cells were analyzed by subsequent binding of 35S-labeled Trcp2, as described for panel A. (C) Immunoblot analysis of Flag-IFNAR1 immunopurified from U3A human cells pretreated with kinase inhibitors and then treated with IFN- as indicated. (D and E) Endogenous IFNAR1 immunoprecipitated from the lysates from 293T cells (treated as indicated) was analyzed as in panel C. (F) Immunoblot analysis of IFNAR1 and STAT1 in mouse embryo fibroblasts not treated (Mock) or treated with IFN- (500 IU/ml) with or without pretreatment with JAK inhibitor I (JI) or PKD inhibitor CID755673 (CID) as indicated.

Journal: Molecular and Cellular Biology

Article Title: Ligand-Stimulated Downregulation of the Alpha Interferon Receptor: Role of Protein Kinase D2

doi: 10.1128/mcb.01154-10

Figure Lengend Snippet: FIG. 1. Pharmacological analyses of IFN-induced phosphorylation of IFNAR1 degron. (A) Binding of 35S-Trcp2 to GST-IFNAR1 (wild type [WT] or S535 539A mutant [SA]) upon their phosphorylation using CK1-depleted lysates from 293T cells treated with IFN- as indicated. Levels of GST-IFNAR1 are analyzed by Coomassie blue staining. The SA mutant migrates more slowly in SDS-PAGE due to the presence of four additional amino acids in the linker (31). (B) The effects of various pharmacologic kinase inhibitors (whose activities were verified in kinase-specific assays; data not shown) on phosphorylation of GST-IFNAR1 by the CK1-depleted lysate from IFN--treated (for 10 min) cells were analyzed by subsequent binding of 35S-labeled Trcp2, as described for panel A. (C) Immunoblot analysis of Flag-IFNAR1 immunopurified from U3A human cells pretreated with kinase inhibitors and then treated with IFN- as indicated. (D and E) Endogenous IFNAR1 immunoprecipitated from the lysates from 293T cells (treated as indicated) was analyzed as in panel C. (F) Immunoblot analysis of IFNAR1 and STAT1 in mouse embryo fibroblasts not treated (Mock) or treated with IFN- (500 IU/ml) with or without pretreatment with JAK inhibitor I (JI) or PKD inhibitor CID755673 (CID) as indicated.

Article Snippet: Antibodies against Flag, GST, and -actin (Sigma), hemagglutinin (HA) (12CA; Roche), CK1 , PKD1/2 (PKC ), PKD3 (PKC ), intracellular domain of hIFNAR1 and PKR (Santa Cruz), anti-pan-phospho-tyrosine (4G10), phospho-STAT1 and STAT1 (Cell Signaling), phospho-S710 of PKD2 (Biosource), PKD2 (Bethyl Laboratories), mIFNAR1 (Leinco), and ubiquitin (FK2; Biomol) were purchased.

Techniques: Phospho-proteomics, Binding Assay, Mutagenesis, Staining, SDS Page, Labeling, Western Blot, Immunoprecipitation

FIG. 6. PKD2 regulates the extent of cellular responses to IFN-. (A) STAT1 Tyr phosphorylation and levels in cells untreated or pretreated with the PKD inhibitor CID755673 for 1 h and then pulse-treated with IFN- for 15 min (followed by removal of cytokine and inhibitor and incubation of cells for the indicated times) were analyzed by immunoblotting. (B) Analysis in cells that received indicated shRNA was carried out as for panel A. (C) Relative activity of ISRE-driven firefly luciferase activity normalized to renilla luciferase activity in 2fTGH cells. Cells were pretreated with the PKD inhibitor CID755673 (for 1 h) and pulse-treated with IFN- (for 0 to 2 h) as indicated, and the activity of luciferase was assessed 24 h later. Data from four independent experiments (each in triplicate) are presented as means standard errors of the mean. (D) Analysis of ISRE-driven transcription in 2fTGH cells that received the indicated shRNA and were pulse-treated with IFN- for the indicated times was carried out as described for panel C. (E) Immunoblot analysis of PKR, STAT1, and -actin levels in 2fTGH cells that received the indicated shRNA were pulse-treated with IFN- for the indicated times and were analyzed 24 h thereafter.

Journal: Molecular and Cellular Biology

Article Title: Ligand-Stimulated Downregulation of the Alpha Interferon Receptor: Role of Protein Kinase D2

doi: 10.1128/mcb.01154-10

Figure Lengend Snippet: FIG. 6. PKD2 regulates the extent of cellular responses to IFN-. (A) STAT1 Tyr phosphorylation and levels in cells untreated or pretreated with the PKD inhibitor CID755673 for 1 h and then pulse-treated with IFN- for 15 min (followed by removal of cytokine and inhibitor and incubation of cells for the indicated times) were analyzed by immunoblotting. (B) Analysis in cells that received indicated shRNA was carried out as for panel A. (C) Relative activity of ISRE-driven firefly luciferase activity normalized to renilla luciferase activity in 2fTGH cells. Cells were pretreated with the PKD inhibitor CID755673 (for 1 h) and pulse-treated with IFN- (for 0 to 2 h) as indicated, and the activity of luciferase was assessed 24 h later. Data from four independent experiments (each in triplicate) are presented as means standard errors of the mean. (D) Analysis of ISRE-driven transcription in 2fTGH cells that received the indicated shRNA and were pulse-treated with IFN- for the indicated times was carried out as described for panel C. (E) Immunoblot analysis of PKR, STAT1, and -actin levels in 2fTGH cells that received the indicated shRNA were pulse-treated with IFN- for the indicated times and were analyzed 24 h thereafter.

Article Snippet: Antibodies against Flag, GST, and -actin (Sigma), hemagglutinin (HA) (12CA; Roche), CK1 , PKD1/2 (PKC ), PKD3 (PKC ), intracellular domain of hIFNAR1 and PKR (Santa Cruz), anti-pan-phospho-tyrosine (4G10), phospho-STAT1 and STAT1 (Cell Signaling), phospho-S710 of PKD2 (Biosource), PKD2 (Bethyl Laboratories), mIFNAR1 (Leinco), and ubiquitin (FK2; Biomol) were purchased.

Techniques: Phospho-proteomics, Incubation, Western Blot, shRNA, Activity Assay, Luciferase